CRL · Charles River Laboratories International, Inc.

This 8-K reports outcomes from Charles River Laboratories’ 2026 Annual Meeting, reflecting routine governance actions with moderate investor significance. The approval of the 2026 Long-Term Incentive Plan is operationally consequential: it establishes a new equity compensation framework with a 4.825 million-share fungible pool, where full-value awards (e.g., RSUs) consume twice the pool allocation of options or SARs — a structural feature that may accelerate dilution pressure over time if heavily utilized for retention. The director elections show broad consensus but notable variance: Abraham Ceesay received over 8.2 million 'against' votes (18.6% of votes cast), the highest dissent among nominees, suggesting potential shareholder concern regarding his board service — though no rationale is disclosed in this filing. All other directors received >97% support. The advisory say-on-pay vote passed comfortably (93.8% in favor), reinforcing alignment on executive compensation design. The auditor ratification passed unanimously among voting shares and uniquely had zero broker non-votes — a procedural signal of strong institutional engagement. No financial results, guidance, or material agreements beyond the incentive plan are disclosed; thus, the filing carries medium materiality — relevant for governance monitoring and equity program modeling, but not for near-term earnings or strategic inflection.